NeuroBo appoints Mark A. Glickman to board of directors

MetaVia Inc.

Appointed effective May 11, 2023 as Class III director, term expiring at 2025 annual meeting.
Glickman brings over 30 years pharma experience; most recently co-CEO of TherapeuticsMD (TXMD).
Will receive standard non-employee director compensation: initial 40,000-share option grant and $40,000 annual cash retainer (pro-rated for 2023).
Company plans Q3 2023 Phase 2a trial for DA-1241 (NASH) and IND for DA-1726 (GLP1R/GCGR) with Phase 1a in H1 2024.
No family relationships or material arrangements with any other director or officer.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark A. Glickman

Class III director

MTVA · MetaVia Inc.

Effective: 2023-05-11
Filed: May 12, 2023, 7:59 PM ET

On May 11, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company” ), on the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee” ), appointed Mark A. Glickman, effective immediately, to serve as a Class III director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark A. Glickman was appointed as Class III director at MetaVia Inc..

Action: appointed
Role: Class III director

Exact text from the filing

On May 11, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company” ), on the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee” ), appointed Mark A. Glickman, effective immediately, to serve as a Class III director

View on SEC.gov

MetaVia Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-009512

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.